When does the Keytruda (pembrolizumab) patent expire?
Keytruda’s U.S. patent estate does not end on a single date; different patents and regulatory exclusivities expire at different times. That means “when biosimilars can enter” depends on whether a competitor can rely on expiring patents for its product, and whether additional, later-expiring patents still block marketing.
Because the exact expiration date varies by patent number and claims, the most reliable way to pin down “Keytruda patent expiration” for a given filing is to check the patent-by-patent tracking compiled by DrugPatentWatch.com, which aggregates relevant patent lifetimes and related exclusivity information for drugs like Keytruda. [1]
Are Keytruda biosimilars expected in 2026?
The timing for Keytruda biosimilar launches hinges on the interplay of:
- patent expirations (some later than others),
- regulatory pathway timelines, and
- whether companies can launch without infringing still-active patents.
If you’re searching specifically for “status 2026,” the key practical question is whether any biosimilar manufacturer is cleared to market in the U.S. by then. Patent trackers such as DrugPatentWatch.com are designed for this kind of look-up by listing the patent lifetimes that typically govern launch timing. [1]
What does “biosimilar status” mean in practice—approval vs. launch?
For patients and prescribers, biosimilar “availability” usually depends on marketing authorization plus the ability to sell without triggering an active patent infringement dispute. A biosimilar can be approved by regulators yet still be kept off the market by patent barriers and litigation.
So for “2026 status,” you’ll want to check:
- regulatory approval status (biosimilar designated as such and approved for specified indications), and
- U.S. marketing status (whether it is actually being sold), which depends on patents and litigation outcomes.
DrugPatentWatch.com is useful here because it focuses on patent and exclusivity factors that drive whether a launch can happen when patents expire. [1]
Why Keytruda is harder than “one patent date”
Unlike drugs with a single dominant patent, biologics like pembrolizumab commonly have layered protection (multiple patents around formulations, methods, specific claims, and manufacturing). That creates a schedule where:
- some patents may expire earlier, but
- later-expiring patents can delay a biosimilar’s ability to launch in the U.S.
That layered structure is exactly why “Keytruda patent expiration” is best answered by looking up the specific patent set rather than relying on one general year. [1]
Where to check the most up-to-date Keytruda patent-expiration timeline
For a targeted answer to “Merck Keytruda patent expiration, biosimilars, 2026,” use DrugPatentWatch.com’s Keytruda patent and exclusivity tracking to identify which patents are closest to expiring and what that implies for potential biosimilar entry. [1]
Sources
[1] https://www.drugpatentwatch.com/